HFCAS OpenIR  > 医学物理与技术中心
Therapeutic hexapeptide (PGPIPN) prevents and cures alcoholic fatty liver disease by affecting the expressions of genes related with lipid metabolism and oxidative stress
Qi, Nan1; Liu, Chen1,2; Yang, Haoran1,3; Shi, Wanrong4; Wang, Shenyi1; Zhou, Yan1; Wei, Cai5; Gu, Fang1; Qin, Yide1
2017-10-20
Source PublicationONCOTARGET
Volume8Issue:50Pages:88079-88093
AbstractPGPIPN is a therapeutic hexapeptide derived from bovine beta-casein. Here we investigated the role and mechanism of this peptide on alcoholic fatty liver disease (AFLD). We took human hepatic cell line LO2 and hepatocellular carcinoma cell line HepG2 to establish the models of steatosis hepatocyte induced by alcohol, taken PGPIPN as pharmacological intervention. And we also established the model of AFLD mice, taken PGPIPN as therapeutic drug and glutathione (GSH) as positive control. We assayed the biochemical materials related to liver injury, lipid metabolism and oxidation, and observed morphology change and fat accumulation of hepatocyte. The gene expressions and/or activities related to liver injury, lipid metabolism and oxidation, such as ACC, PPAR-gamma, CHOP and Caspase-3, were assessed by real time PCR and western blot. Our results showed PGPIPN alleviated hepatic steatosis in both model cells and AFLD model mice. PGPIPN can effectively reduce the lipid accumulation and oxidative stress of hepatocyte in a dose-dependent manner. PGPIPN alleviated alcohol-induced cell steatosis and injuries by regulating the gene expressions and/or activities of ACC, PPAR-gamma, CHOP and Caspase-3. Our results demonstrated PGPIPN had the protective and therapeutic effect on AFLD, which may serve as a potential therapeutic agent for AFLD.
SubtypeArticle
KeywordSpgpipn Alcoholic Fatty Liver Steatosis Gene Expression
WOS HeadingsScience & Technology ; Life Sciences & Biomedicine
Funding OrganizationNational Natural Science Foundation of China(81472448 ; Province Natural Science Foundation of Anhui(1508085MH196) ; Provincial Natural Science Research Project of Anhui(KJ2017A182 ; National Undergraduate Training Programs for Innovation and Entrepreneurship of China(201510366035) ; 30872992) ; KJ2016A336) ; National Natural Science Foundation of China(81472448 ; Province Natural Science Foundation of Anhui(1508085MH196) ; Provincial Natural Science Research Project of Anhui(KJ2017A182 ; National Undergraduate Training Programs for Innovation and Entrepreneurship of China(201510366035) ; 30872992) ; KJ2016A336)
DOI10.18632/oncotarget.21404
WOS KeywordNF-KAPPA-B ; BIOACTIVE PEPTIDES ; INJURY ; MANAGEMENT ; APOPTOSIS ; PROTEINS ; RATS
Indexed BySCI
Language英语
Funding OrganizationNational Natural Science Foundation of China(81472448 ; Province Natural Science Foundation of Anhui(1508085MH196) ; Provincial Natural Science Research Project of Anhui(KJ2017A182 ; National Undergraduate Training Programs for Innovation and Entrepreneurship of China(201510366035) ; 30872992) ; KJ2016A336) ; National Natural Science Foundation of China(81472448 ; Province Natural Science Foundation of Anhui(1508085MH196) ; Provincial Natural Science Research Project of Anhui(KJ2017A182 ; National Undergraduate Training Programs for Innovation and Entrepreneurship of China(201510366035) ; 30872992) ; KJ2016A336)
WOS Research AreaOncology ; Cell Biology
WOS SubjectOncology ; Cell Biology
WOS IDWOS:000413341400087
Citation statistics
Cited Times:1[WOS]   [WOS Record]     [Related Records in WOS]
Document Type期刊论文
Identifierhttp://ir.hfcas.ac.cn:8080/handle/334002/33833
Collection医学物理与技术中心
Affiliation1.Anhui Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Hefei 230032, Anhui, Peoples R China
2.Guangming Ctr Hosp, Clin Lab, Shenzhen 518107, Guangdong, Peoples R China
3.Chinese Acad Sci, Hefei Inst Phys Sci, Ctr Med Phys & Technol, Hefei 230031, Anhui, Peoples R China
4.Anhui Med Univ, Dept Internal Med, Affiliated Hosp 4, Hefei 230022, Anhui, Peoples R China
5.Anhui Med Univ, Affiliated Hosp 2, Dept Pharm, Hefei 230601, Anhui, Peoples R China
Recommended Citation
GB/T 7714
Qi, Nan,Liu, Chen,Yang, Haoran,et al. Therapeutic hexapeptide (PGPIPN) prevents and cures alcoholic fatty liver disease by affecting the expressions of genes related with lipid metabolism and oxidative stress[J]. ONCOTARGET,2017,8(50):88079-88093.
APA Qi, Nan.,Liu, Chen.,Yang, Haoran.,Shi, Wanrong.,Wang, Shenyi.,...&Qin, Yide.(2017).Therapeutic hexapeptide (PGPIPN) prevents and cures alcoholic fatty liver disease by affecting the expressions of genes related with lipid metabolism and oxidative stress.ONCOTARGET,8(50),88079-88093.
MLA Qi, Nan,et al."Therapeutic hexapeptide (PGPIPN) prevents and cures alcoholic fatty liver disease by affecting the expressions of genes related with lipid metabolism and oxidative stress".ONCOTARGET 8.50(2017):88079-88093.
Files in This Item: Download All
File Name/Size DocType Version Access License
Therapeutic hexapept(9229KB)期刊论文作者接受稿开放获取CC BY-NC-SAView Download
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Qi, Nan]'s Articles
[Liu, Chen]'s Articles
[Yang, Haoran]'s Articles
Baidu academic
Similar articles in Baidu academic
[Qi, Nan]'s Articles
[Liu, Chen]'s Articles
[Yang, Haoran]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Qi, Nan]'s Articles
[Liu, Chen]'s Articles
[Yang, Haoran]'s Articles
Terms of Use
No data!
Social Bookmark/Share
File name: Therapeutic hexapeptide (PGPIPN) prevents and cures alcoholic fatty liver disease by affecting the expressions of genes related with lipid metabolism and oxidative stress.pdf
Format: Adobe PDF
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.